Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Atopic Dermatitis and Skin Disease
  Follow Topic   Edit Search
Your search returned 9 results
from the time period: last 30 days.
Sort by Relevance / Date Group By Journal / No Grouping
The British journal of dermatology
... IL36RN, CARD14 and AP1S3 have been identified to cause/ contribute to pustular skin diseases, primarily generalized pustular psoriasis (GPP) AbstractText: To better understand the disease-relevance of these genes, we screened our cohorts of patients with pustular skin diseases (primarily GPP and palmoplantar pustular psoriasis [PPP]) for coding changes in these ...
Dermatology (3)
Psoriasis (3), Skin Diseases (3), Acute Generalized Exanthematous Pustulosis (1), more mentions
The Journal of allergy and clinical immunology
Astrotactin 1-derived peptide (AP): a new skin-penetrating peptide against inflammatory skin diseases"..
Skin Diseases (2), more mentions
The Journal of allergy and clinical immunology
Abstract: Until the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, systemic immunosuppressants. The pipeline of more targeted topical and systemic therapies is expanding based on our growing understanding of the mechanism for AD and is particularly focused on suppressing the skewed immune activation.
Dermatology (2)
Atopic Dermatitis (2), Pruritus (1), more mentions
The British journal of dermatology
... clinical signs and symptoms in adults with moderate-to-severe atopic dermatitis (AD) in a randomized, double-blind, placebo-controlled, phase 2a ... QoLIAD) score (exploratory outcome) and its correlation with efficacy outcomes (Eczema Area and Severity Index [EASI; primary endpoint], SCORing Atopic Dermatitis [SCORAD], SCORAD visual analogue scale [VAS] scores for sleep and ...
Dermatology (4)
Pruritus (7), Atopic Dermatitis (4), Eczema (2), more mentions
The Journal of investigative dermatology
Living in a hard water area is associated with an increased risk of atopic dermatitis (AD. Greater skin barrier impairment following exposure to surfactants in wash products combined with high calcium, and/or chlorine, levels in hard water is a compelling mechanism for this increase. The purpose of this study was to investigate this mechanism in individuals with and without ...
Dermatology (2)
Atopic Dermatitis (2), more mentions
Journal of the American Academy of Dermatology
Potential impact of biologics and emerging therapies for psoriasis and atopic dermatitis on future fertility: Reassurance to patients but more data are needed..
Dermatology (4)
Atopic Dermatitis (2), Psoriasis (2), more mentions
The Journal of investigative dermatology
Previous transcriptome analyses underscored the importance of immunological and skin barrier abnormalities in atopic dermatitis (AD. We sought to identify novel pathogenic pathways involved in AD by comparing the transcriptomes of AD patients stratified for filaggrin (FLG) null mutations to those of both healthy donors and patients with ichthyosis vulgaris (IV.
Dermatology (2)
Atopic Dermatitis (2), Ichthyosis Vulgaris (2), more mentions
The British journal of dermatology
A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment..
Dermatology (2)
Atopic Dermatitis (2), more mentions
The Journal of allergy and clinical immunology
miRNA-155 contributes to the inflammatory process in AD by regulating the expression of the high-affinity receptor for IgE (FcεRI) via its transcription factor PU.1. miRNA-155 may represent an interesting new target in AD therapy.